Does SGLT2 inhibitors reduce the incidence of atrial fibrillation/atrial flutter in patients with type 2 diabetes mellitus/heart failure?
This systematic review and meta-analysis explores the potential of SGLT2 inhibitors to affect the incidence of atrial fibrillation and atrial flutter in patients with type 2 diabetes or heart failure.
This article provides a new direction for the use of SGLT2i, and hopefully it can provide certain theoretical basis for the broader clinical indications of SGLT2i in the future.
Wang et al. (Sun,) studied this question.